Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloStim immunotherapy vs Physician's Choice in advanced hepatocellular carcinoma
NCT05033522Phase 3Suspended
- Sponsor
- Mirror Biologics, Inc.
- Start
- Aug 2023
- Primary completion
- Nov 2026
- Modality
- Native Immune Cells
- Countries
- 2
01
Overview
A Phase 3 trial of allostim in hepatocellular carcinoma (HCC), sponsored by Mirror Biologics, Inc.. Started Aug 2023; status: suspended.
02
Drugs
allostim
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05033522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033522.